0000921895-20-003153.txt : 20201201
0000921895-20-003153.hdr.sgml : 20201201
20201201194550
ACCESSION NUMBER: 0000921895-20-003153
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201127
FILED AS OF DATE: 20201201
DATE AS OF CHANGE: 20201201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Powell David Jonathan
CENTRAL INDEX KEY: 0001824493
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36866
FILM NUMBER: 201362106
MAIL ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Summit Therapeutics Inc.
CENTRAL INDEX KEY: 0001599298
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-514-7149
MAIL ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Therapeutics plc
DATE OF NAME CHANGE: 20150219
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Corp plc
DATE OF NAME CHANGE: 20140205
4
1
form412566003_12012020.xml
OWNERSHIP DOCUMENT
X0306
4
2020-11-27
0
0001599298
Summit Therapeutics Inc.
SMMT
0001824493
Powell David Jonathan
ONE BROADWAY
14TH FLOOR
CAMBRIDGE
MA
02142
0
1
0
0
Chief Scientific Officer
Common Stock
2020-11-27
4
M
0
16616
1.92
A
16616
D
Common Stock
2020-11-27
4
M
0
12953
1.79
A
29569
D
Common Stock
2020-11-27
4
S
0
29569
4.39
D
0
D
Common Stock
2020-11-30
4
M
0
13713
1.79
A
13713
D
Common Stock
2020-11-30
4
S
0
13713
4.44
D
0
D
Stock Option (right to buy)
1.92
2020-11-27
4
X
0
16616
1.92
D
2028-10-19
Common Stock
16616
417639
D
Stock Option (right to buy)
1.79
2020-11-27
4
X
0
12953
1.79
D
2029-03-29
Common Stock
12953
404686
D
Stock Option (right to buy)
1.79
2020-11-30
4
X
0
13713
1.79
D
2029-03-29
Common Stock
13713
390973
D
Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices.
The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.30 to $4.66. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.40 to $4.50. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date.
The option was granted on March 29, 2019. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date.
/s/ Michael Paul Donaldson, Attorney-in-Fact
2020-12-01